Medication use is often underreported in paper-based questionnaires or interviews. Web-based questionnaires may improve recall of medication use, but data on their validity are currently lacking. Participants in the Pregnancy and Infant Development (PRIDE) Study (2014)(2015)(2016); n = 557) and the Pregnancy Drug Registry (pREGnant) (2015)(2016); n = 169) completed a 6-week paper-based medication diary during gestational weeks 19-24 or 26-31. In week 34, they completed a Web-based questionnaire with questions on medication names, time period and frequency of use, and quantity taken. To assess the degree of underreporting, we calculated the questionnaire's sensitivity using the medication diary as the reference standard. Sensitivity was high for many medication groups, including antiepileptic medication (sensitivity (Sn) = 0.96, 95% confidence interval (CI): 0.89, 1.00), antacids (Sn = 0.89, 95% CI: 0.86, 0.93), and iron preparations (Sn = 0.81, 95% CI: 0.64, 0.98). However, medications for short-term use were underreported more frequently, with sensitivities of 0.54 (95% CI: 0.35, 0.72) for antihistamines, 0.63 (95% CI: 0.57, 0.69) for analgesic and antipyretic agents, and 0.57 (95% CI: 0.51, 0.64) for acetaminophen. Shortening the period of time between exposure and questionnaire administration increased sensitivity substantially. In conclusion, underreporting in Web-based questionnaires is limited for many medication groups. In prospective studies, underreporting of medications for short-term use may be reduced by decreasing the interval between consecutive questionnaires.
In developed countries, it is estimated that 29%-99% of pregnant women take at least 1 prescription medication, depending on the data sources used and the types of medication included (1) . Although some medications, such as thalidomide and isotretinoin, are classical examples of human teratogens, the human safety profile is undetermined for over 90% of prescription medication treatments that have been approved for marketing in the United States since 1980 (2) . Due to lack of information, pregnant women and their treating physicians are often concerned about the potential risks of medication for the developing embryo or fetus. As a result, compliance with pharmacological treatment for maternal disorders may decrease, which in turn may endanger maternal and fetal health. Therefore, epidemiologic studies that assess associations between medication use and adverse pregnancy outcomes are urgently needed.
Collecting valid data on medication use during pregnancy is challenging, however. Individual prescription or medical records or registries may overestimate prescription medication use, since compliance among pregnant women may be low, particularly for medication used for local or short-term treatment (3) . In addition, these data sources usually do not contain information on use of over-the-counter (OTC) medications. However, previous studies indicated that prescription medication use is underreported in paper-based questionnaires or interviews (4) (5) (6) (7) (8) (9) (10) , whereas data on the validity of self-reported OTC medication use during pregnancy are scarce. If it is nondifferential, misclassification of medication exposure status during pregnancy resulting from noncompliance and underreporting may lead to false-negative results in risk assessment studies (3, 11) .
The amount and quality of data obtained on medication use during pregnancy via self-reported methods of data collection depends on the type of medication of interest and on the specificity of the questions asked. Structured questions about indications for use and specific medication names are more successful in gathering reports of use than open-ended questions (12, 13) . In line with these recommendations, we developed Web-based questionnaires to assess medication use in 2 prospectively enrolled cohorts of pregnant women. In these questionnaires, indication-oriented questions were used, after which tailored multiple-choice questions with relevant medications for the specific indication were shown. The aim of this study was to validate these Web-based questionnaires to assess medication use during pregnancy, using medication diaries as the reference standard. This enabled us to validate OTC medication use as well, which was impossible in previous studies comparing self-reported data with prescription records. Furthermore, we determined whether selected characteristics, including maternal factors and timing of the questionnaire, influenced underreporting in the questionnaire.
METHODS
This study was embedded in 2 ongoing prospective cohort studies being conducted among pregnant women in the Netherlands. The Pregnancy and Infant Development (PRIDE) Study aims at identifying factors that affect the health of the mother or her child at any point in time during or after pregnancy (14) , whereas the Pregnancy Drug Registry (pREGnant) (https:// www.pregnant.nl/) is a national registry for medication use during pregnancy and lactation at the Netherlands Pharmacovigilance Centre Lareb (https://www.lareb.nl/en/) that aims to provide information on the safety of medication use. In both cohorts, participating midwives and gynecologists invited pregnant women aged ≥18 years to participate just before or during their first prenatal care visit (usually gestational weeks [8] [9] [10] [11] [12] . The women were asked to complete Web-based questionnaires at baseline, during gestational weeks 17 and 34, and at multiple time points after delivery. The prenatal questionnaires included questions on demographic characteristics, maternal health (including medication use), obstetric history, and lifestyle factors. Since data collection for the International Registry of Antiepileptic Drugs and Pregnancy (EURAP) (15) in the Netherlands is embedded in pREGnant, women with epilepsy were oversampled. PRIDE Study participants with an estimated date of delivery between February 2014 and May 2016 (n = 1,950) and pREGnant participants with an estimated date of delivery between January 2015 and January 2016 (n = 627) were eligible for participation in this validation study. The Regional Committee on Research Involving Human Subjects approved of the creation of both cohorts. All participants gave their informed consent digitally.
Ascertainment of medication use
In the baseline and follow-up questionnaires, medication use was assessed using a comprehensive indication-oriented structure.
When a participant reported pharmacological treatment for an indication, information on the generic and brand names was collected through closed-ended questions, as well as information on the time period of use (i.e., use during the entire period, specification of starting and stopping dates, or use during an unknown time period between 2 successive questionnaires), frequency of use, and quantity taken.
Furthermore, using openended questions, we assessed whether medication was used for any other conditions or complaints. In the Web Video (available at https://academic.oup.com/aje), we give a demonstration of the questions about medication use posed in the Web-based questionnaire. In the PRIDE Study questionnaires, the indications that triggered the medication questions were clustered in a separate questionnaire section. Information on medication use from previous questionnaires was not incorporated into the follow-up questionnaires. In the pREGnant questionnaires, however, the medication questions were immediately triggered when a woman indicated the presence of a medical condition or complication. If it was still applicable, information on medication use provided in the preceding questionnaire was shown and the participant needed only to indicate changes in usage pattern and time period of use.
During the study period, participants in both studies were asked to complete a 6-week paper-based medication diary following completion of the Web-based questionnaire administered in gestational week 17. Women who agreed to complete the 6-week diary were randomized to receive the diary directly after completing this questionnaire (usually starting in gestational week 19) or in week 25 (for completion in gestational weeks 26-31). Through these diaries, information on the exact name of the medication, daily dose, and time period of use was collected. On the first page, respondents could write down the name of any medication used on a daily basis to decrease respondent burden. We sent a reminder if the diary was not returned within 2 weeks.
We coded all medications reported in the Web-based questionnaire administered at gestational week 34 and in the paper-based diary using the Anatomical Therapeutic Chemical classification (16) and the indication, if necessary. Use of vaccines (Anatomical Therapeutic Chemical codes J05, J06, and J07), vitamin supplements (including folic acid), and homeopathic preparations was excluded from this study, as the participants may not have considered these substances to be medications. We ordered the medications into 3 mutually exclusive categories based on the classification of Bakker et al. (17) : medications for chronic conditions, medications for occasional and short-term use, and pregnancy-related medications (Web Table 1 ). Medications for chronic conditions did not have to be taken on a regular basis but may have been used on an as-needed basis as well.
Statistical analysis
We defined use of prescribed and OTC medication as reported in the diaries as our reference standard. Women who reported not completing the medication questions in the questionnaire because they had already provided this information in the diary were excluded from the analyses. We focused the analyses on sensitivity, for 3 reasons: 1) previous validation studies identified underreporting of medication use as the main limitation of the traditional modes of data collection (i.e., paper-based questionnaires and interviews); 2) the diary did not cover the entire time period between the 2 consecutive questionnaires; and 3) a substantial proportion of women in our study did not report the starting and stopping dates of medication use in the questionnaire. This measure, including its 95% confidence interval, was calculated for the individual medications and groups of medications, if there were at least 10 exposures according to the diary. A woman was considered exposed to a certain medication according to the Web-based questionnaire when she reported any use of that medication. Furthermore, we stratified by cohort and by duration of time between completion of the diary and completion of the Web-based questionnaire.
For medications with 10 or more true-positive subjects, we compared the daily dose reported in the questionnaire with the daily dose from the diary. Although it was impossible to calculate the questionnaire's specificity for the above-mentioned reasons, we evaluated potential overreporting by checking whether medication that was reported to be used in the entire time period between the questionnaires administered at 17 and 34 weeks of gestation was mentioned in the diary as well. In a sensitivity analysis, we excluded the women who returned the diary after completing the questionnaire.
We used logistic regression analysis to evaluate whether selected maternal characteristics, including maternal age, country of birth, level of education, prepregnancy body mass index (weight (kg)/height (m) 2 ), gravidity, parity, fertility problems, use of folic acid during the recommended period (from 4 weeks prior to pregnancy through gestational week 10), and smoking or alcohol use during pregnancy, were associated with underreporting in the questionnaire. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 22 (IBM Corporation, Armonk, New York).
RESULTS
Of the women who were eligible for participation, 35.7% of PRIDE Study participants (697/1,950) and 35.4% of pREGnant participants (222/627) agreed to complete the diary. A total of 589 (84.5%) and 175 (78.8%) completed diaries were returned by PRIDE Study and pREGnant participants, respectively. Of these 764 women, 28 did not complete the Web-based questionnaire administered at gestational week 34, and 9 had already given birth before questionnaire administration. In addition, 1 woman was excluded for not completing the medication questions in the questionnaire due to having filled in the diary. This left 726 women for analysis in this validation study: 557 from the PRIDE Study and 169 from pREGnant (Web Figure 1) .
The characteristics of the women in the complete cohorts and of the participating women are shown in Table 1 . Compared with the complete cohorts, participating women were more likely to have a high level of education. Among women participating in this validation study, PRIDE Study participants had a higher level of education than did pREGnant participants and were more likely to have been born in the Netherlands. pREGnant participants were slightly older and more likely to have used folic acid supplements during the recommended period than PRIDE Study participants (69.8% and 49.2%, respectively).
A total of 464 women (63.9%) reported use of 152 different medications in the 6-week diary, with acetaminophen (31.8%) and ordinary salt combinations (16.9%; mainly Rennie (Bayer BV, Mijdrecht, the Netherlands), which contains calcium carbonate/magnesium carbonate) being used most frequently. The sensitivity of the questionnaire with regard to medication groups used for chronic conditions ranged between 0.55 (95% confidence interval (CI): 0.25, 0.84) for antidepressants and 0.96 (95% CI: 0.89, 1.00) for antiepileptic medication (Table 2) . For groups of medications that are for occasional and short-term use, sensitivity ranged between 0.30 (95% CI: 0.10, 0.50) and 0.70 (95% CI: 0.50, 0.90) for antifungal agents for dermatological use and antibacterial agents for systemic use, respectively, while for pregnancy-related medication groups, it ranged between 0.60 (95% CI: 0.35, 0.85) for gynecological antiinfectives and antiseptics and 0.89 (95% CI: 0.86, 0.93) for antacids. For the individual medications that had at least 10 exposures, sensitivity ranged between 0.18 (95% CI: 0.00, 0.36) for nasal saline and 0.91 (95% CI: 0.74, 1.00) for levetiracetam. Sensitivity seemed somewhat lower for medications that were mainly available without a prescription as compared with prescription medication, ranging between 0.18 (95% CI: 0.00, 0.36) for nasal saline and 0.76 (95% CI: 0.69, 0.84) for ordinary salt combinations. Exclusion of women who returned the diary after completing the questionnaire (n = 146; 20.1%) did not materially change the results (data not shown).
The results obtained after stratification for duration of time between completion of the diary and completion of the questionnaire are shown in Table 3 . In general, sensitivity seemed to be higher when the questionnaire was administered sooner after completing the diary, particularly for salbutamol A notable exception was the use of antidepressants, which seemed to be reported better when there was more time between completion of the diary and completion of the questionnaire (Sn = 0.33 vs. Sn = 0.80). We did not observe statistically significant differences in sensitivity between the PRIDE Study and pREGnant questionnaires (Table 4) .
For 7 of the 9 individual medications with 10 or more truepositive subjects, the questionnaire and the diary were in agreement regarding the daily dose for more than 75% of women (Web Table 2 )-levothyroxine (70%) and xylometazoline (53%) being exceptions. Both underreporting and overreporting of the daily dose occurred in the questionnaire, and only a few women did not report the daily dose.
A total of 4 individual medications and 7 medication groups were included in the exploratory analysis on potential overreporting in the Web-based questionnaire (Table 5 ). For antiepileptic medication, thyroid therapy, and analgesics and antipyretics, no false-positive reports were identified. For both antiasthmatic agents and laxatives, 1 woman reported continuous exposure in the Web-based questionnaire, whereas she reported no use in the diary. However, these women reported use at the lowest frequency possible (<3 times/week and <1 time/ day), so they may not have experienced an episode requiring pharmacological treatment during the diary period. Use of ear, eye, nose, and throat preparations and antacids seemed to be overreported by 46% and 20% of women who reported continuous use in the Web-based questionnaire, respectively. Most of the overreported antacid use (n = 7) concerned use <1 time/day. Table 6 shows the odds ratios and 95% confidence intervals for the associations between maternal characteristics and underreporting of medication use in the Web-based questionnaire. Underreporting was increased among women with a The 95% CI could not be estimated due to the lack of false negatives (Sn = 1) or true positives (Sn = 0). b ACE Pharmaceuticals BV, Zeewolde, the Netherlands. Abbreviations: CI, confidence interval; FN, false-negative; pREGnant, Pregnancy Drug Registry; PRIDE, Pregnancy and Infant Development; Sn, sensitivity; TP, true-positive.
a The 95% CI could not be estimated due to the lack of false negatives (Sn = 1) or true positives (Sn = 0). b ACE Pharmaceuticals BV, Zeewolde, the Netherlands.
a low/intermediate level of education compared with women with a high level of education (university of applied sciences or research university) for medication used for chronic conditions (odds ratio (OR) = 2.8, 95% CI: 1.1, 6.9) and medication intended for occasional or short-term use (OR = 1.7, 95% CI: 1.0, 3.0). The latter may also have been underreported more frequently by women under age 25 years (OR = 2.5, 95% CI: 0.8, 7.9) and women with fertility problems (OR = 2.0, 95% CI: 1.0, 4.1). Being overweight (OR = 2.0, 95% CI: 0.9, 4.3) or obese (OR = 6.6, 95% CI: 2.4, 18.0) before pregnancy increased underreporting of pregnancy-related medication and possibly of chronic medication as well. Furthermore, underreporting of pregnancy-related medication seemed to occur more often among women with at least 1 previous pregnancy or live birth (OR = 1.9, 95% CI: 1.0, 3.6). We did not find associations between underreporting in the questionnaire and the other characteristics, including country of birth, use of folic acid during the recommended period, and smoking and alcohol use during pregnancy.
DISCUSSION
The results of this validation study showed that the sensitivity of indication-oriented Web-based questionnaires to assess prescription and OTC medication use during pregnancy was generally high for medications used for chronic conditions and somewhat lower for most pregnancy-related medications, but substantially lower for medications intended for occasional and short-term use. However, shortening the time period between exposure and questionnaire administration increased sensitivity to a great extent. Pregnant women seemed to report the daily dose of the most commonly used medications well. A low/intermediate level of education, being overweight or obese before pregnancy, fertility problems, and having had 1 or more previous pregnancies or liveborn infants were associated with underreporting of medication use in the Web-based questionnaire. For the majority of medications selected, overreporting was negligible.
To the best of our knowledge, this is the first study validating Web-based questionnaires to assess medication use. Because it is not feasible to incorporate all recommendations about questionnaire design (i.e., structured questions about indications and specific medication names instead of open-ended questions) into paper-based questionnaires, we expected less underreporting in our Web-based questionnaires. Although it was still not optimal, the sensitivity of the Web-based questionnaires to assess medication use during pregnancy was indeed generally higher than that of paper-based questionnaires validated in previous studies (4, 8, 9, 18) . For example, comparing sensitivities for antacids (Sn = 0.89 in our study vs. Sn = 0.15-0.26 in previous studies), antibacterials for systemic use (Sn = 0.70 vs. Sn = 0.09-0.27), and iron preparations (Sn = 0.81 vs. Sn = 0.54-0.60) yields large differences between the two methods of data collection. These differences were less evident for most medications for chronic conditions (e.g., antiasthmatic agents (Sn = 0.79 vs. Sn = 0.17-0.79) and thyroid medication (Sn = 0.79 vs. Sn = 0.82)). In most previous studies, however, questionnaires were administered after giving birth, which may have influenced recall as well.
Our study indicated that sensitivity was substantially improved when the Web-based questionnaire was administered sooner after medication use, particularly for medications for occasional and short-term use. This is in line with previous studies, in which researchers concluded that disagreement between questionnaires and a reference standard was reduced when the questionnaire was administered sooner after delivery (8, 19, 20) . In light of these findings, it may be advisable to assess medication use during pregnancy frequently in prospective studies-for instance, every 2 months-to optimize data quality. Because some maternal characteristics, including educational level, prepregnancy body mass index, fertility problems, and parity, were associated with underreporting of medication use not only in our study but also in previous studies (21) (22) (23) (24) , any improvement in data collection may reduce the risk of differential misclassification.
Use of medication diaries as the reference standard was the major strength of this validation study. Previous studies almost all used medical or pharmacy records as reference standards, which may cause overestimation of prescription medication use if patients are not checked for compliance. Furthermore, it is impossible to validate OTC medication use with pharmacy records, whereas these medications, such as acetaminophen and most antacids, were the most frequently used medications in our study population. However, because the 6-week diary only covered part of the time period referred to in the Web-based questionnaire (±17 weeks) and some women did not report the starting and stopping dates of medication use in the questionnaire, we could not evaluate its specificity. Reassuringly, false-positive reporting of medication use during pregnancy Abbreviations: pREGnant, Pregnancy Drug Registry; PRIDE, Pregnancy and Infant Development.
a Only medications or medication groups with at least 10 subjects who reported having used the medication during the entire time period between the 2 Web-based questionnaires are shown.
was generally uncommon in our exploratory analysis and in previous studies, which found specificities greater than or equal to 0.97 (7) (8) (9) . Only Sundermann et al. (10) reported a lower specificity (specificity = 0.62), for recall of exposure to nonsteroidal antiinflammatory drugs using first-trimester interviews with diary data as the reference standard, but their period of interest also included the week before the last menstrual period. The relatively high rates of overreporting of use of ear, eye, nose, and throat preparations and antacids in our study population may be attributable to overestimation of the time period of use in the questionnaire, as both groups of medications are intended for occasional or short-term use; occasional use may be difficult to report in a questionnaire. Because of the frequently missing medication starting and stopping dates in the questionnaire and the current lack of knowledge on the relevant exposure time window for many adverse perinatal outcomes, we defined any use in the time period between the two questionnaires as "positive." This decision might have caused us to overestimate sensitivity, as the medication use episode reported in the questionnaire may not correspond to use in the diary period in cases of multiple periods of exposure. Other strengths of this study included the relatively large sample size, though many individual medications could still not be formally validated, and the ability to validate the daily dose for the most commonly used medications.
Our study also had some limitations. The PRIDE Study and pREGnant both have relatively low response rates, and women participating in these cohort studies represent, for the most part, a highly educated population, possibly hampering the generalizability of our results. In addition, women who did not use medication at the time we asked for participation in the diary study may have been less likely to consent to participate. Although participants were not informed about the objective of the diaries, completing the diaries might have increased recall in the questionnaire. A home inventory might provide a superior measure of prescription and OTC medication use (25) , but using this method of data collection in such a large sample of pregnant women was infeasible. Finally, we validated the second followup questionnaire administered to these prospectively enrolled cohorts, which may have been completed more accurately than the baseline and first follow-up questionnaires due to a learning effect.
In conclusion, information on prescription and OTC medication use during pregnancy can be collected validly using Webbased questionnaires in prospective studies, provided that the time interval between 2 consecutive questionnaires does not exceed approximately 2 months. Even if questionnaires are administered less frequently, sensitivity may be considered sufficient for most medications used for chronic conditions and some pregnancy-related medications.
